Pharmaceutical

KP-910 by Kaken Pharmaceutical for Peripheral Neuropathic Pain: Likelihood of Approval

KP-910is under clinical development by Kaken Pharmaceutical and currently in Phase I for Peripheral Neuropathic Pain.

Jul 1, 2023 - 20:00
KP-910is under clinical development by Kaken Pharmaceutical and currently in Phase I for Peripheral Neuropathic Pain.
Read the original article

Tags:

Previous Article

[177Lu]Lu-rhPSMA-10.1 by Blue Earth Therapeutics for Metastatic Castration-Resis...

Next Article

(Glucagon + insulin human) by Abvance Therapeutics for Hypoglycemia: Likelihood ...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

AstraZeneca posts 81% rise in FY 2023 profit after tax

AstraZeneca posts 81% rise in FY 2023 profit after tax

Feb 10, 2024

CMO Moves: Regulatory catalysts for drug manufacturing – March 2023

CMO Moves: Regulatory catalysts for drug manufacturing ...

Mar 21, 2023

Japan approves updated Covid-19 vaccine to tackle JN.1 variant

Japan approves updated Covid-19 vaccine to tackle JN.1 ...

Sep 14, 2024